A Company Called StrokeDx Just Cleared a Device That Is Not Cleared to Detect Stroke
- NeuraNova received FDA 510(k) clearance for the STEDI Device, a bioimpedance spectroscopy system that measures impedance ratios to help assess cerebral fluid volume asymmetry between the brain’s hemispheres in adults undergoing neurological assessment.
- It is portable, noninvasive and designed for bedside use in hospitals, giving clinicians rapid physiologic readings without imaging. The cleared label positions it strictly as an adjunct to standard clinical evaluation.
- This is the company’s first FDA clearance. NeuraNova was previously named StrokeDx, and raised a $5 million seed prime round in 2024.
- Two further platforms, FLASH (handheld) and PinPoint (bedside neuronavigation), remain in development and are not cleared.
CI read
The gap between the label and the ambition is the whole story. What is cleared is narrow and carefully worded: a device that measures fluid asymmetry between hemispheres, as an adjunct, not a diagnostic. What the company was built to do is obvious from its former name. Bedside triage of suspected stroke without a scanner is one of the largest unmet needs in acute neurology, because the constraint on treatment is time to imaging, and imaging is where the queue forms. Clearing a physiologic measurement is the entry ticket to that problem, not the solution to it. The rename from StrokeDx to NeuraNova, alongside two further platforms in development, says the company is deliberately building a portable neuro-sensing portfolio rather than a single stroke product. Watch what indication the next submission claims, because that is where the real value sits and where the regulatory difficulty begins.